Age and sex disparities in drug shortage impacts: a 10-year nationwide study in France
Laëtitia Belgodère, Christopher Leleu, Trystan Bacon, Pascale Daynes, Christophe Decoene, Patrick Feugier, Roseline Mazet, Thierry Vial, Stéphane Vignot, Mehdi Benkebil, Wahiba Oualikene-Gonin, Patrick Maison

TL;DR
This study shows that drug shortages in France disproportionately affect older adults and women, highlighting health inequalities.
Contribution
The study provides the first nationwide analysis of age and sex disparities in drug shortage impacts over a 10-year period.
Findings
Older patients (≥60 years) were more affected by most therapeutic classes during drug shortages.
Women had higher exposure to drug shortages across all major therapeutic categories.
Younger patients and men showed higher use of specific drug classes like anti-infectives and renin–angiotensin agents.
Abstract
Drug shortages are a growing public health issue, unevenly impacting therapeutic classes. Despite variations in drug consumption across populations, the consequences of these shortages on different patient groups remain insufficiently characterized. This study investigated age and sex profiles of patients consuming the therapeutic classes most commonly affected by drug shortages in France. The age and sex risk of shortage exposure were estimated in a nationwide retrospective study of French patients between 2014 and 2023, using data from the French drug shortage notification system and the national health insurance for the entire French population. Over 10 years, 17 505 drug shortage reports were recorded, 60.8% involving cardiovascular, nervous system, and anti-infective agents. Significantly higher mean percentages of consumers for drugs concerned by shortage reports per 1000 were…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPharmaceutical Economics and Policy · Health Systems, Economic Evaluations, Quality of Life · Pharmaceutical industry and healthcare
